Bookmark and Share
Metformin (CID 4091) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(16)
 
 
Inactive(265)
 
 
Inconclusive(31)
 
 
Unspecified(2344)
 
 
Top Targets:
p450(19)
 
 
 
 
7TM GPCR Srx(17)
 
 
7TM GPCR Srsx(15)
 
 
NR LBD ER(9)
 
 
 
MFS(8)
 
 
BioAssay Types:
Literature(305)
 
 
 
 
 
Confirmatory(189)
 
 
 
Summary(24)
 
 
 
Screening(3)
 
 
BioActivity Types:
IC50(697)
 
 
 
 
Potency(180)
 
 
 
AC50(2)
 
 
EC50(1)
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 2583    Data Row: 2656   Total Pages: 54   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103508547]
EC50 0.27Increase in glucose consumption in insulin-resistant human HepG2 cells after 24 hrs [AID619463, Type: Literature]
View
2
[SID103508547]
IC50 29Inhibition of DPP4 [AID313842, Type: Literature]
View
3
[SID48416229]
DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database [AID1195, Type: other]
View
4
[SID103508547]
Antidiabetic activity in high fat diet-fed C57BL/6J mouse assessed as decrease in blood glucose level at 250 mg/kg/day, po for 4 weeks measured after 60 mins by intraperitoneal glucose tolerance test [AID615040, Type: Literature]
View
5
[SID103508547]
Antidiabetic activity in high fat diet-fed C57BL/6J mouse assessed as decrease in blood glucose level at 250 mg/kg/day, po for 4 weeks measured after 120 mins by intraperitoneal glucose tolerance test [AID615041, Type: Literature]
View
6
[SID103508547]
Antidiabetic activity in normal ICR mouse assessed as reduction in plasma glucose level at 200 mg/kg, ip after 60 mins [AID654702, Type: Literature]
View
7
[SID103508547]
Antidiabetic activity in STZ-induced ICR mouse T1DM model assessed as reduction in plasma glucose level at 200 mg/kg, ip after 60 mins [AID654703, Type: Literature]
View
8
[SID103508547]
Antiproliferative activity against human MDA-MB-231 cells at 1 to 20 mM after 24 hrs by MTT assay [AID658424, Type: Literature]
View
9
[SID103508547]
Antiobesity activity in Wistar rat high fat diet-induced NAFLD model assessed as reduction of fat accumulation in liver at 150 mg/kg, po qd for 4 weeks by hematoxylin and eosin staining [AID705285, Type: Literature]
View
10
[SID103508547]
Reduction of glucose consumption in insulin-resistant human HepG2 cells at 1 mM after 24 hrs by glucose oxidase method in presence of 0.1 uM of insulin [AID705326, Type: Literature]
View
11
[SID103508547]
Reduction of glucose consumption in insulin-resistant human HepG2 cells at 1 mM after 24 hrs by glucose oxidase method in presence of 22.2 mM of glucose [AID705327, Type: Literature]
View
12
[SID103508547]
Antiobesity activity in C57BL/6J mouse high fat diet-induced NAFLD model assessed as reduction of postprandial glucose level at 150 mg/kg, po qd for 6 weeks by intravenous glucose tolerance test [AID705073, Type: Literature]
View
13
[SID103508547]
Antiobesity activity in C57BL/6J mouse high fat diet-induced NAFLD model assessed as reduction of postprandial glucose level at 150 mg/kg, po qd for 6 weeks by oral glucose tolerance test [AID705075, Type: Literature]
View
14
[SID103508547]
Antidiabetic activity in C57BLKS/J-db/db mouse assessed as reduction of fasting blood glucose level at 250 mg/kg/day, po for 5 weeks [AID615133, Type: Literature]
View
15
[SID103508547]
Antiobesity activity in C57BL/6J mouse high fat diet-induced NAFLD model assessed as reduction of fat mass in epididymal and abdominal at 150 mg/kg, po qd for 7 weeks [AID705088, Type: Literature]
View
16
[SID103508547]
Antiobesity activity in C57BL/6J mouse high fat diet-induced NAFLD model assessed as reduction of liver weight at 150 mg/kg, po qd for 7 weeks [AID705089, Type: Literature]
View
17
[SID103508547]
IC50 250Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay [AID721754, Type: Literature]Multidrug and toxin extrusion protein 1 [gi:74731723]
View
18
[SID103508547]
Km 377TP_TRANSPORTER: uptake in OCT1-expressing CHO cells [AID679316, Type: other]Solute carrier family 22 member 1 [gi:81872095]
View
19
[SID103508547]
IC50 378.253SANGER: Inhibition of human KASUMI-1 cell growth in a cell viability assay. [AID742267, Type: other]
View
20
[SID103508547]
IC50 510.565SANGER: Inhibition of human LU-65 cell growth in a cell viability assay. [AID742331, Type: other]
View
21
[SID103508547]
IC50 533.964SANGER: Inhibition of human NCI-H720 cell growth in a cell viability assay. [AID741766, Type: other]
View
22
[SID103508547]
IC50 556.027SANGER: Inhibition of human MOLT-13 cell growth in a cell viability assay. [AID742372, Type: other]
View
23
[SID103508547]
IC50 701.245SANGER: Inhibition of human HCC2218 cell growth in a cell viability assay. [AID742200, Type: other]
View
24
[SID103508547]
IC50 838.321SANGER: Inhibition of human DU-145 cell growth in a cell viability assay. [AID742124, Type: other]
View
25
[SID103508547]
IC50 925.298SANGER: Inhibition of human NCI-H209 cell growth in a cell viability assay. [AID741726, Type: other]
View
26
[SID103508547]
IC50 1056.64SANGER: Inhibition of human KU812 cell growth in a cell viability assay. [AID742287, Type: other]
View
27
[SID103508547]
IC50 1313.48SANGER: Inhibition of human NCI-H510A cell growth in a cell viability assay. [AID741753, Type: other]
View
28
[SID103508547]
IC50 1486.9SANGER: Inhibition of human ML-2 cell growth in a cell viability assay. [AID742368, Type: other]
View
29
[SID103508547]
IC50 1531.55SANGER: Inhibition of human KY821 cell growth in a cell viability assay. [AID742289, Type: other]
View
30
[SID103508547]
IC50 1591.69SANGER: Inhibition of human G-401 cell growth in a cell viability assay. [AID742170, Type: other]
View
31
[SID103508547]
IC50 1700TP_TRANSPORTER: inhibition of Cimetidine uptake (Cimetidine: 1 uM) in Xenopus laevis oocytes [AID680369, Type: other]Solute carrier family 22 member 2 [gi:313104182]
View
32
[SID103508547]
IC50 1816.07SANGER: Inhibition of human EoL-1-cell cell growth in a cell viability assay. [AID742166, Type: other]
View
33
[SID103508547]
IC50 1970.61SANGER: Inhibition of human CTV-1 cell growth in a cell viability assay. [AID742089, Type: other]
View
34
[SID103508547]
IC50 2010TP_TRANSPORTER: inhibition of Cimetidine uptake (Cimetidine: 1 uM) in Xenopus laevis oocytes [AID680364, Type: other]Solute carrier family 22 member 1 [gi:313104181]
View
35
[SID103508547]
IC50 2283.3SANGER: Inhibition of human ECC10 cell growth in a cell viability assay. [AID742134, Type: other]
View
36
[SID103508547]
IC50 2720.84SANGER: Inhibition of human CCRF-CEM cell growth in a cell viability assay. [AID742058, Type: other]
View
37
[SID103508547]
IC50 2756.33SANGER: Inhibition of human P30-OHK cell growth in a cell viability assay. [AID741803, Type: other]
View
38
[SID103508547]
IC50 2900.9SANGER: Inhibition of human ALL-PO cell growth in a cell viability assay. [AID741961, Type: other]
View
39
[SID103508547]
IC50 3017.5SANGER: Inhibition of human BV-173 cell growth in a cell viability assay. [AID741988, Type: other]
View
40
[SID103508547]
IC50 3045.59SANGER: Inhibition of human KARPAS-45 cell growth in a cell viability assay. [AID742266, Type: other]
View
41
[SID103508547]
IC50 3174.75SANGER: Inhibition of human LCLC-97TM1 cell growth in a cell viability assay. [AID742316, Type: other]
View
42
[SID103508547]
IC50 3262.01SANGER: Inhibition of human D-423MG cell growth in a cell viability assay. [AID742106, Type: other]
View
43
[SID103508547]
IC50 3357.98SANGER: Inhibition of human CAL-54 cell growth in a cell viability assay. [AID742006, Type: other]
View
44
[SID103508547]
IC50 3398.02SANGER: Inhibition of human KOSC-2 cell growth in a cell viability assay. [AID742280, Type: other]
View
45
[SID103508547]
IC50 3697.15SANGER: Inhibition of human NCI-SNU-5 cell growth in a cell viability assay. [AID741777, Type: other]
View
46
[SID103508547]
IC50 3835.95SANGER: Inhibition of human DU-4475 cell growth in a cell viability assay. [AID742125, Type: other]
View
47
[SID103508547]
IC50 4008.41SANGER: Inhibition of human TCCSUP cell growth in a cell viability assay. [AID741928, Type: other]
View
48
[SID103508547]
IC50 4099.72SANGER: Inhibition of human NCI-H1770 cell growth in a cell viability assay. [AID741711, Type: other]
View
49
[SID103508547]
IC50 4116.33SANGER: Inhibition of human CW-2 cell growth in a cell viability assay. [AID742090, Type: other]
View
50
[SID103508547]
IC50 4195.07SANGER: Inhibition of human BT-549 cell growth in a cell viability assay. [AID741987, Type: other]
View